All In Biotech

Drug Trial Radar · NCT07285655

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 344 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

344

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Jul 2029

Study completion Dec 2031

Sponsor

Lead sponsor
Liquidia Technologies, Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.

Conditions

  • Pulmonary Hypertension Due to Lung Disease (Disorder)

Interventions

  • L606Drug

    L606 is a liposomal version of treprostinil intended for delivery via oral inhalation using a study issued nebulizer.

  • PlaceboDrug

    Placebo will match L606 but contain no treprostinil.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in 6-minute walk distance (6MWD) as evaluated by the 6-minute walk test (6MWT)Time frame: 16 weeks

Locations

44 sites in 12 countries. Site status is shown where the registry gives one.

  • Dignity Health - St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • Arizona Pulmonary Specialists, Ltd.

    Scottsdale, Arizona · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • National Jewish Hospital

    Denver, Colorado · Recruiting

  • Tampa General Hospital

    Tampa, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • St. Vincent Cardiovascular Research Institute

    Indianapolis, Indiana · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Summit Health

    Bend, Oregon · Recruiting

  • Medical University of South Carolina- Nexus Research Clinic

    Charleston, South Carolina · Recruiting

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia · Recruiting

  • Ordensklinikum Linz GmbH

    Linz, Austria · Recruiting

  • Hopital Erasme

    Anderlecht, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Peter Lougheed Center

    Calgary, Canada · Recruiting

  • Hospices Civils De Lyon

    Bron, France · Recruiting

  • Assistance Publique Hopitaux De Paris

    Le Kremlin-Bicêtre, France · Recruiting

  • Universitaetsklinikum Koeln AöR

    Cologne, Germany · Recruiting

  • Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen GmbH

    Essen, Germany · Recruiting

  • Universitätsklinikum Giessen und Marburg - Standort Giessen

    Giessen, Germany · Recruiting

  • Universitaetsmedizin Greifswald KöR

    Greifswald, Germany · Recruiting

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Recruiting

  • Krankenhaus Neuwittelsbach

    Munich, Germany · Recruiting

  • LMU Klinikum Muenchen AöR

    Munich, Germany · Recruiting

  • IRCCS Ospedale Policlinico San Martino

    Genoa, Italy · Recruiting

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Policlinico Umberto I

    Rome, Italy · Recruiting

  • Pauls Stradinš Clinical University Hospital

    Riga, Latvia · Recruiting

  • Unidade Local De Saude De Almada-Seixal E.P.E.

    Almada, Portugal · Recruiting

  • Unidade Local De Saude De Coimbra E.P.E.

    Coimbra, Portugal · Recruiting

  • Unidade Local De Saude De Santo Antonio E.P.E.

    Porto, Portugal · Recruiting

  • Hospital Del Mar

    Barcelona, Spain · Recruiting

  • Hospital Clinic De Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario Marques De Valdecilla

    Santander, Spain · Recruiting

  • Royal United Hospitals Bath NHS Foundation Trust

    Bath, United Kingdom · Recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.